Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ROCHE HOLDINGS AG : Receives a Buy rating from UBS

share with twitter share with LinkedIn share with facebook
09/18/2020 | 05:24am EDT

Michael Leuchten from UBS retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at CHF 390.

© MarketScreener with dpa-AFX Analyser 2020

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG -2.57% 299.15 Delayed Quote.-2.21%
UBS GROUP AG -0.89% 11.12 Delayed Quote.-8.22%
share with twitter share with LinkedIn share with facebook
All news about ROCHE HOLDING AG
03:54pROCHE : COVID SCIENCE-COVID-19 complication rates far higher than for flu; open ..
RE
01:36pPROTHENA : Shares Rise 7% on Prasinezumab Study With Roche
DJ
09:22aPTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
DJ
07:57aROCHE : and Prothena will Advance Prasinezumab into Late-Stage Clinical Developm..
AQ
10/20ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/20Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..
AQ
10/19ROCHE : Genentech Announces Full FDA Approval for Venclexta Combinations for Acu..
AQ
10/19ROCHE HOLDINGS AG : JP Morgan reaffirms its Buy rating
MD
10/19ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/19ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
PU
More news
Financials
Sales 2020 60 427 M 66 754 M 66 754 M
Net income 2020 14 685 M 16 223 M 16 223 M
Net cash 2020 3 204 M 3 539 M 3 539 M
P/E ratio 2020 17,7x
Yield 2020 3,10%
Capitalization 256 B 283 B 283 B
EV / Sales 2020 4,18x
EV / Sales 2021 3,85x
Nbr of Employees 97 735
Free-Float 83,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 379,15 CHF
Last Close Price 299,15 CHF
Spread / Highest target 47,8%
Spread / Average Target 26,7%
Spread / Lowest Target 3,63%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-2.21%289 156
JOHNSON & JOHNSON-0.90%380 575
PFIZER INC.-3.52%208 327
MERCK & CO., INC.-13.94%197 964
NOVARTIS AG-15.38%188 853
NOVO NORDISK A/S16.64%166 534